for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Halozyme Therapeutics, Inc.

HALO.OQ

Latest Trade

33.85USD

Change

-1.42(-4.03%)

Volume

444,595

Today's Range

33.50

 - 

35.43

52 Week Range

33.50

 - 

56.27

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
35.27
Open
34.74
Volume
444,595
3M AVG Volume
16.00
Today's High
35.43
Today's Low
33.50
52 Week High
56.27
52 Week Low
33.50
Shares Out (MIL)
140.79
Market Cap (MIL)
4,765.64
Forward P/E
13.33
Dividend (Yield %)
--

Next Event

Halozyme Therapeutics Inc at Evercore ISI HealthCONx Virtual Conference

Latest Developments

More

Halozyme Reports Q3 2021 Results

Halozyme Reports Second Quarter 2021 Results

Halozyme Announces Janssen Receives U.S. FDA Approval Of DARZALEX FASPRO In Combination With Pomalidomide And Dexamethasone

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. is a biopharma technology platform company. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine its ENHANZE drug delivery technology with the collaborators' compounds. The Company's lead enzyme, rHuPH20, is used to facilitate the delivery of injected drugs and fluids. The Company's approved product and its collaborators’ approved products and product candidates are based on rHuPH20, a patented recombinant human hyaluronidase enzyme. The Company's lead product, Hylenex recombinant, is a formulation of rHuPH20 that facilitates subcutaneous fluid administration for achieving hydration, to increase the dispersion and absorption of other injected drugs and, in subcutaneous urography, to improve resorption of radiopaque agents. Its pipeline products include Herceptin SC, HYQVIA, DARZALEX and others.

Industry

Biotechnology & Drugs

Contact Info

11388 Sorrento Valley Rd

SAN DIEGO, CA

92121-1345

United States

+1.858.7948889

https://www.halozyme.com/

Executive Leadership

Connie L. Matsui

Independent Chairman of the Board

Helen I. Torley

President, Chief Executive Officer, Director

Elaine D. Sun

Chief Financial Officer, Senior Vice President

Michael J. LaBarre

Senior Vice President, Chief Technical Officer

Masaru Matsuda

Senior Vice President, Chief Compliance Officer, General Counsel, Company Secretary

Key Stats

2.25 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.2K

2019

0.2K

2020

0.3K

2021(E)

0.4K
EPS (USD)

2018

-0.560

2019

-0.500

2020

0.910

2021(E)

2.540
Price To Earnings (TTM)
12.15
Price To Sales (TTM)
10.29
Price To Book (MRQ)
16.94
Price To Cash Flow (TTM)
11.56
Total Debt To Equity (MRQ)
310.89
LT Debt To Equity (MRQ)
279.21
Return on Investment (TTM)
52.14
Return on Equity (TTM)
47.86

Latest News

Latest News

BRIEF-GlaxoSmithKline Says VIIV/Halozyme Sign Exclusive Licensing Agreement

* GLAXOSMITHKLINE PLC - VIIV/HALOZYME SIGN EXCLUSIVE LICENSING AGREEMENT

Genmab shares drop on legal battle with J&J over cancer drug

Shares in Danish biotech firm Genmab <GMAB.CO> fell as much as 14% on Wednesday after it said it was locked in a legal battle with its partner Johnson & Johnson <JNJ.N> over royalty payments for its key cancer drug.

BRIEF-Halozyme To Receive $10 Million Milestone Payment From Janssen

* HALOZYME TO RECEIVE $10 MILLION MILESTONE PAYMENT FROM JANSSEN

BRIEF-Halozyme To Receive $15 Mln Milestone Payment From Janssen

* HALOZYME TO RECEIVE $15 MILLION MILESTONE PAYMENT FROM JANSSEN

BRIEF-Halozyme Reports Q1 Loss Per Share $0.04

* Q1 EARNINGS PER SHARE ESTIMATE $-0.02 -- REFINITIV IBES DATA

BRIEF-Janssen Submits NDA In Japan For Daratumumab Subcutaneous Formulation Utilizing Halozyme's Enhanze Tech For Patients With Multiple Myeloma

* JANSSEN SUBMITS NDA IN JAPAN FOR DARATUMUMAB SUBCUTANEOUS FORMULATION UTILIZING HALOZYME'S ENHANZE TECH FOR PATIENTS WITH MULTIPLE MYELOMA Source text for Eikon: Further company coverage:

BRIEF-Artisan Partners Limited Partnership Reports 10.5% Passive Stake In Halozyme Therapeutics

* ARTISAN PARTNERS LIMITED PARTNERSHIP REPORTS 10.5% PASSIVE STAKE IN HALOZYME THERAPEUTICS INC AS OF MARCH 31- SEC FILING Source text : (https://bit.ly/34pGO5F) Further company coverage:

BRIEF-Halozyme Says FDA Accepted BLA For Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Enhanze® Technology

* HALOZYME ANNOUNCES FDA HAS ACCEPTED BIOLOGICS LICENSE APPLICATION FOR FIXED-DOSE SUBCUTANEOUS COMBINATION OF PERJETA® AND HERCEPTIN® USING ENHANZE® TECHNOLOGY

BRIEF-Halozyme Says Elaine Sun Has Been Appointed CFO

* HALOZYME THERAPEUTICS INC - ELAINE D. SUN HAS BEEN APPOINTED SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, EFFECTIVE MARCH 2, 2020

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up